التفاصيل البيبلوغرافية
العنوان:
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
المؤلفون:
Edi Brogi , Doyel Mitra , Samuel M. Lesko , Yun Zhu , Stella U. Okamgba , Tamika Duplessis , Frank E. Jones , Michael J. Brumlik , Jenny G. Parvani
المصدر:
Molecular Cancer Therapeutics . 8:2152-2162
بيانات النشر:
American Association for Cancer Research (AACR), 2009.
سنة النشر:
2009
مصطلحات موضوعية:
Cancer Research , Receptor, ErbB-2 , medicine.drug_class , Fluorescent Antibody Technique , Antineoplastic Agents , Breast Neoplasms , Antibodies, Monoclonal, Humanized , Transfection , Tyrosine-kinase inhibitor , Mice , Breast cancer , Trastuzumab , Cell Line, Tumor , Animals , Humans , Protein Isoforms , Medicine , Neoplasm , skin and connective tissue diseases , neoplasms , business.industry , Antibodies, Monoclonal , medicine.disease , Gene Expression Regulation, Neoplastic , Dasatinib , Oncology , Drug Resistance, Neoplasm , Immunology , NIH 3T3 Cells , Cancer research , Female , Signal transduction , business , Tyrosine kinase , Signal Transduction , medicine.drug , Proto-oncogene tyrosine-protein kinase Src
الوصف:
The HER2-targeted therapy trastuzumab is widely used for the treatment of patients with metastatic breast tumors overexpressing HER2. However, an objective response is observed in only 12% to 24% of patients treated with trastuzumab as a single agent and initial responders regress in
تدمد:
1538-8514
DOI:
10.1158/1535-7163.mct-09-0295
URL الوصول:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87bcde6dda4c17824e13f460cdaba0a6 https://doi.org/10.1158/1535-7163.mct-09-0295
Rights:
OPEN
رقم الانضمام:
edsair.doi.dedup.....87bcde6dda4c17824e13f460cdaba0a6
قاعدة البيانات:
OpenAIRE